IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4759
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$264M
Faraz Ali
Tenaya Therapeutics, Inc. discovers, develops, and delivers therapies for heart disease in the United States. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) and gDCM. It is also developing a small molecule inhibitor of histone deacetylase 6 for use in heart failure with preserved ejection fraction (HFpEF)
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TNYA Tenaya Therapeutics, Inc. | 25 | 24 | 28 | 13 | - | - | -115.9% | -91.5% | - | - | - | - | 0.0% | 27.0x | $264M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Tenaya Therapeutics, Inc. (TNYA) receives a "Avoid" rating with a composite score of 25.3/100. It ranks #4759 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for TNYA.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 24 | 6 | +18ALPHA |
| MOMENTUM | 13 | 5 | +8ALPHA |
| VALUATION | 28 | 17 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 19 | 6 | +13ALPHA |
| SHORT INT | 27 | 16 | +11ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -115.9% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Tenaya Therapeutics, Inc. (TNYA) as Avoid with a composite score of 25.3/100 at a current price of $0.61. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Tenaya Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 25.3/100 places it at rank #4759 in our full universe.
No Moat
High
Poor
Fair Value
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Tenaya Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Tenaya Therapeutics, Inc. with an Avoid rating, assigning a composite score of 25.3/100 and 1 out of 5 stars. Ranked #4759 of 7,333 stocks, TNYA falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Tenaya Therapeutics, Inc. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -115.9% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
TNYA registers a value score of just 28/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.62x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Tenaya Therapeutics, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -91.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Tenaya Therapeutics, Inc. is experiencing notably weak momentum with a score of just 13/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.74 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Tenaya Therapeutics, Inc. registers a low stability score of 19/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.74 and a debt-to-equity ratio of 27.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Tenaya Therapeutics, Inc.'s short interest score of 27/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.74), elevated leverage (D/E: 27.00x), micro-cap liquidity risk. At $264M (micro-cap), TNYA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Tenaya Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4759 of 7,333 overall (35th percentile). Key comparisons include ROE of -115.9% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TNYA currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (13) would have the largest impact on the composite score.
ROE 6001% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 12757% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Tenaya Therapeutics Inc. (NASDAQ:TNYA) is one of the overlooked growth stocks to buy.
On January 8, 2026, TheFly reported that Morgan Stanley reduced its price target on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) from $5 to $2, while reiterating an ‘Overweight’ rating.
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results. Blend Labs posted quarterly loss of 9 cents per share, in-line with market estimates of 9 cents per share. The company’s quarterly sales came in at $36.10 million versus estimates of $36.93 million, according to data from Benzinga Pro. Blend Labs shares jumped 24.3% to $2.92 on Friday. Here are some other big stocks recording gains in today’s session. Cardlytics, Inc. (NASDAQ: CDLX) jumped 57.1% to $12.86 after the company reported better-than-expected fourth-quarter earnings. American Vanguard Corporation (NYSE: AVD) rose 25.8% to $13.32 following fourth-quarter financial results. Tredegar Corporation (NYSE:
Why Tenaya Therapeutics Is Back on Investors’ Radar Tenaya Therapeutics (TNYA) recently completed a US$60 million capital raise, extending its cash runway into mid-2027. This is a key development for a company funding clinical-stage gene therapy programs for heart disease. See our latest analysis for Tenaya Therapeutics. Despite the fresh funding, Tenaya’s recent share price performance has been weak, with a 90 day share price return showing a 56% decline and a 1 year total shareholder return...
Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway. See our latest analysis for Tenaya Therapeutics. At a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term...